Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) EPS (Basic) (2020 - 2023)

Candel Therapeutics' EPS (Basic) history spans 4 years, with the latest figure at -$0.38 for Q4 2023.

  • For Q4 2023, EPS (Basic) fell 123.53% year-over-year to -$0.38; the TTM value through Dec 2023 reached -$1.3, down 103.12%, while the annual FY2024 figure was -$1.74, 32.82% down from the prior year.
  • EPS (Basic) for Q4 2023 was -$0.38 at Candel Therapeutics, down from -$0.29 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.63 in Q4 2021 and bottomed at -$1.47 in Q2 2021.
  • The 4-year median for EPS (Basic) is -$0.3 (2022), against an average of -$0.32.
  • The largest annual shift saw EPS (Basic) surged 220.41% in 2021 before it plummeted 900.0% in 2023.
  • A 4-year view of EPS (Basic) shows it stood at -$0.52 in 2020, then surged by 220.41% to $0.63 in 2021, then crashed by 126.98% to -$0.17 in 2022, then plummeted by 123.53% to -$0.38 in 2023.
  • Per Business Quant, the three most recent readings for CADL's EPS (Basic) are -$0.38 (Q4 2023), -$0.29 (Q3 2023), and -$0.33 (Q2 2023).